Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018

-- Conference Call Scheduled for 11:00 a.m. EDT --

SAN DIEGO, July 19, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will hold a conference call to discuss financial results and business highlights for the quarter ended June 30, 2018, as follows:

Date	Thursday August 2, 2018
Time	11:00 a.m. EDT
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Passcode	2086111
Webcast (live and archived)	www.evofem.com under " <u>Investors</u> " or <u>click here</u>

The teleconference replay will be available approximately two hours after completion through Tuesday, August 7, 2018, at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The replay access code is 2086111. The archived webcast will be available via the aforementioned URLs.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.

Evofem Biosciences' Contact

Amy Raskopf Investor Relations <u>araskopf@evofem.com</u> 858-550-1900 x167

SOURCE Evofem Biosciences, Inc.